Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Receivables - Other (2016 - 2018)

Historic Receivables - Other for Arcadia Biosciences (RKDA) over the last 5 years, with Q4 2018 value amounting to $3000.0.

  • Arcadia Biosciences' Receivables - Other fell 2500.0% to $3000.0 in Q4 2018 from the same period last year, while for Dec 2018 it was $3000.0, marking a year-over-year decrease of 2500.0%. This contributed to the annual value of $3000.0 for FY2018, which is 2500.0% down from last year.
  • Latest data reveals that Arcadia Biosciences reported Receivables - Other of $3000.0 as of Q4 2018, which was down 2500.0% from $168000.0 recorded in Q3 2018.
  • In the past 5 years, Arcadia Biosciences' Receivables - Other registered a high of $431000.0 during Q3 2015, and its lowest value of $3000.0 during Q4 2018.
  • In the last 5 years, Arcadia Biosciences' Receivables - Other had a median value of $112000.0 in 2017 and averaged $143823.5.
  • As far as peak fluctuations go, Arcadia Biosciences' Receivables - Other plummeted by 9782.61% in 2017, and later surged by 17540.98% in 2018.
  • Over the past 5 years, Arcadia Biosciences' Receivables - Other (Quarter) stood at $380000.0 in 2014, then crashed by 78.42% to $82000.0 in 2015, then soared by 124.39% to $184000.0 in 2016, then plummeted by 97.83% to $4000.0 in 2017, then dropped by 25.0% to $3000.0 in 2018.
  • Its last three reported values are $3000.0 in Q4 2018, $168000.0 for Q3 2018, and $106000.0 during Q2 2018.